Pfizer Inc.

PFENYSEHealthcare● Active

$25.88

$-0.16(-0.61%)

Market Cap$147.5B

P/E Ratio—

52W High$28.75

52W Low$23.08

Avg Volume37.1M

Open$25.97

Beta0.29

Free Cash Flow Financials Revenue

Pfizer Inc. (PFE) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PFE · free cash flow · updated Jun 8, 2026

Core FCF metrics

PFE · FCF · TTM · margin & CAGR

Free cash flow was $9.08B for FY2025 (fiscal year ending 2025-12-31), down 7.7% year-over-year The FCF margin was 14.5%. Five-year CAGR stands at -4.8%.

FY2025 Free Cash Flow$9.08B▼ -7.7% YoY

Trailing 12M (TTM)$9.48Btrailing 4 quarters sum

FCF Margin14.5%$9.08B ÷ revenue

3-Year CAGR-29.6%FY2022 → FY2025

5-Year CAGR-4.8%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

PFE · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$11.71B(2.63B)$9.08B▼ 7.7%14.5%

FY2024$12.74B(2.91B)$9.84B▲ +105.2%15.5%

FY2023$8.70B(3.91B)$4.79B▼ 81.6%8.1%

FY2022$29.27B(3.24B)$26.03B▼ 12.8%25.9%

FY2021$32.58B(2.71B)$29.87B▲ +157.2%36.7%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

PFE · P/FCF · FCF yield · FCF per share

Pfizer Inc. (PFE) trades at a FCF yield of 6.39% and a price-to-free-cash-flow ratio of 15.5x. FCF per share stands at $1.67, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

6.39%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$1.67

TTM FCF ÷ Shares Outstanding

Price / FCF

x15.5

Share Price ÷ FCF per Share

EV / FCF (TTM)

x22.3

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

PFE · cash flow statement · operating / investing / financing

For FY2025, Pfizer Inc. generated $11.71B in operating cash flow and spent 2.63B in capital expenditures, yielding $9.08B in free cash flow.

Operating Activities

+$11.71B

Cash from core business operations

2025-12-31

Investing Activities

−$1.35B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$10.30B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($11.71B) − |CapEx| (2.63B) = FCF ($9.08B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

PFE vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Pfizer Inc.YOU

PFE

$9.08B-7.7%14.5%

46%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Pfizer Inc. (PFE) reported free cash flow of $9.08B for FY2025 (fiscal year ending 2025-12-31), down 7.7% year-over-year. The FCF margin was 14.5%.

Based on available data, Pfizer Inc. has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $29.87B in FY2021. The 5-year CAGR stands at -4.8%.

Pfizer Inc.'s FCF yield is 6.39% and price-to-FCF ratio is 15.5x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

PFE free cash flow · 8 questions

Pfizer Inc. free cash flow was $9.08B for FY2025, down 7.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $9.48B.

PFE free cash flowPFE FCFPFE FCF 2025PFE free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Pfizer Inc. · Pfizer Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026